A detailed history of Morgan Stanley transactions in Cellectis S.A. stock. As of the latest transaction made, Morgan Stanley holds 86,325 shares of CLLS stock, worth $157,111. This represents 0.0% of its overall portfolio holdings.

Number of Shares
86,325
Previous 84,145 2.59%
Holding current value
$157,111
Previous $222,000 27.48%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Oct 17, 2024

BUY
$1.86 - $3.35 $4,054 - $7,303
2,180 Added 2.59%
86,325 $161,000
Q2 2024

Aug 14, 2024

BUY
$1.86 - $3.35 $4,054 - $7,303
2,180 Added 2.59%
86,325 $161,000
Q1 2024

Oct 17, 2024

SELL
$2.41 - $3.09 $5,253 - $6,736
-2,180 Reduced 2.53%
84,145 $222,000
Q1 2024

Aug 16, 2024

BUY
$2.41 - $3.09 $19,087 - $24,472
7,920 Added 10.39%
84,145 $222,000
Q1 2024

May 15, 2024

BUY
$2.41 - $3.09 $19,087 - $24,472
7,920 Added 10.39%
84,145 $222,000
Q4 2023

Aug 16, 2024

SELL
$0.97 - $3.55 $9,797 - $35,855
-10,100 Reduced 11.7%
76,225 $234,000
Q4 2023

Feb 13, 2024

BUY
$0.97 - $3.55 $8,374 - $30,647
8,633 Added 12.77%
76,225 $234,000
Q3 2023

Nov 15, 2023

SELL
$1.58 - $2.86 $15,104 - $27,341
-9,560 Reduced 12.39%
67,592 $106,000
Q2 2023

Aug 14, 2023

SELL
$1.72 - $2.12 $946 - $1,166
-550 Reduced 0.71%
77,152 $151,000
Q1 2023

May 15, 2023

BUY
$1.83 - $3.84 $6,516 - $13,674
3,561 Added 4.8%
77,702 $149,000
Q4 2022

Feb 14, 2023

SELL
$1.85 - $2.6 $3,352 - $4,711
-1,812 Reduced 2.39%
74,141 $155,000
Q3 2022

Nov 14, 2022

SELL
$2.29 - $4.08 $54,955 - $97,911
-23,998 Reduced 24.01%
75,953 $174,000
Q2 2022

Oct 27, 2022

BUY
$2.39 - $4.93 $41,922 - $86,477
17,541 Added 21.29%
99,951 $283,000
Q2 2022

Aug 15, 2022

BUY
$2.39 - $4.93 $41,922 - $86,477
17,541 Added 21.29%
99,951 $283,000
Q1 2022

Oct 27, 2022

SELL
$3.45 - $8.77 $60,516 - $153,834
-17,541 Reduced 17.55%
82,410 $374,000
Q1 2022

May 13, 2022

SELL
$3.45 - $8.77 $129,571 - $329,374
-37,557 Reduced 31.31%
82,410 $374,000
Q4 2021

Feb 14, 2022

SELL
$8.01 - $12.84 $67,163 - $107,663
-8,385 Reduced 6.53%
119,967 $974,000
Q3 2021

Nov 15, 2021

BUY
$11.94 - $16.09 $1.53 Million - $2.07 Million
128,352 New
128,352 $1.62 Million

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $82.8M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.